| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Ting-Chun Yeh | Q89578183 |
| P2093 | author name string | Hann-Chorng Kuo | |
| Po-Cheng Chen | |||
| Yann-Rong Su | |||
| P2860 | cites work | Botulinum Toxin as a Biological Weapon: Medical and Public Health Management | Q23832736 |
| The neural control of micturition | Q24619130 | ||
| Implications for bidirectional signaling between afferent nerves and urothelial cells-ICI-RS 2014 | Q26766226 | ||
| Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons | Q27339199 | ||
| Childhood symptoms and events in women with interstitial cystitis/painful bladder syndrome | Q43366391 | ||
| Neonatal urinary bladder inflammation produces adult bladder hypersensitivity | Q43518401 | ||
| Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder | Q44013297 | ||
| Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. | Q44045350 | ||
| Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis | Q44686684 | ||
| Subcutaneous administration of botulinum toxin A reduces formalin-induced pain | Q44722571 | ||
| Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats | Q45062115 | ||
| OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. | Q45907261 | ||
| Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. | Q45940311 | ||
| Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats | Q46566035 | ||
| Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder | Q46741008 | ||
| Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation | Q46816115 | ||
| Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome | Q47194025 | ||
| Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial | Q48621733 | ||
| Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease | Q28079052 | ||
| Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception | Q28084583 | ||
| Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy | Q28246355 | ||
| Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction | Q28370786 | ||
| Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium | Q33671401 | ||
| Neonatal bladder inflammation alters activity of adult rat spinal visceral nociceptive neurons | Q33743682 | ||
| TRPA1 mediates bladder hyperalgesia in a mouse model of cystitis | Q33758307 | ||
| Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis | Q33924099 | ||
| Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). | Q34202884 | ||
| Lamina propria: the functional center of the bladder? | Q34357069 | ||
| The Role of the Mucosa in Normal and Abnormal Bladder Function | Q34528370 | ||
| Drug Insight: biological effects of botulinum toxin A in the lower urinary tract | Q35057523 | ||
| Visceral pain: the neurophysiological mechanism | Q35164413 | ||
| Botulinum toxin: mechanisms of action | Q36009295 | ||
| Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. | Q36373708 | ||
| Activation of extracellular signal-regulated protein kinase 5 is essential for cystitis- and nerve growth factor-induced calcitonin gene-related peptide expression in sensory neurons | Q36411493 | ||
| Increased bladder permeability in interstitial cystitis/painful bladder syndrome | Q36445359 | ||
| MicroRNA-mediated GABA Aα-1 receptor subunit down-regulation in adult spinal cord following neonatal cystitis-induced chronic visceral pain in rats | Q36503179 | ||
| Chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: are they related? | Q36576053 | ||
| Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury | Q36737852 | ||
| Early in life bladder inflammation alters opioid peptide content in the spinal cord and bladder of adult female rats | Q36921219 | ||
| Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm | Q36939434 | ||
| The nature of immune responses to urinary tract infections | Q37050386 | ||
| Animal models and their use in understanding lower urinary tract dysfunction. | Q37739960 | ||
| The afferent system and its role in lower urinary tract dysfunction | Q37871311 | ||
| Contemporary management of the painful bladder: a systematic review | Q37932774 | ||
| Botulinum neurotoxin for pain management: insights from animal models | Q37954278 | ||
| Transient receptor potential channels in bladder function | Q38056773 | ||
| Botulinum toxins: mechanisms of action, antinociception and clinical applications | Q38084073 | ||
| The use of botulinum toxin for the treatment of urologic pain. | Q38139145 | ||
| The long journey of botulinum neurotoxins into the synapse | Q38561450 | ||
| Current and potential urological applications of botulinum toxin A. | Q38564108 | ||
| Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology | Q39207459 | ||
| Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A | Q39387872 | ||
| 125I-Labelled botulinum a neurotoxin: Pharmacokinetics in cats after intramuscular injection | Q39392708 | ||
| Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients | Q39900595 | ||
| Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves | Q41486002 | ||
| Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection | Q43177955 | ||
| Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. | Q50474899 | ||
| TRPV1 is involved in stretch-evoked contractile changes in the rat autonomous bladder model: a study with piperine, a new TRPV1 agonist. | Q50706971 | ||
| Contractile mechanisms coupled to TRPA1 receptor activation in rat urinary bladder. | Q50733695 | ||
| Retrograde transport of radiolabelled botulinum neurotoxin type A to the CNS after intradetrusor injection in rats. | Q51030193 | ||
| Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis. | Q54357961 | ||
| Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis--clinical results and immunohistoc | Q54505136 | ||
| The Expanding Therapeutic Utility of Botulinum Neurotoxins. | Q55105284 | ||
| Botulinum Toxin for Central Neuropathic Pain. | Q55498097 | ||
| Sensor Mechanism and Afferent Signal Transduction of the Urinary Bladder: Special Focus on transient receptor potential Ion Channels | Q57653248 | ||
| Visceral Pain | Q58086445 | ||
| Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA | Q60923153 | ||
| Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome | Q60958347 | ||
| TRP Channels as Lower Urinary Tract Sensory Targets. | Q64915134 | ||
| Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis | Q66829551 | ||
| Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients | Q68331136 | ||
| Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis | Q71062449 | ||
| Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry | Q73118138 | ||
| Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins | Q73426186 | ||
| Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results | Q74206910 | ||
| Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats | Q78413122 | ||
| Long-distance retrograde effects of botulinum neurotoxin A | Q81006671 | ||
| Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder | Q81018432 | ||
| Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome | Q83947318 | ||
| Central origin of the antinociceptive action of botulinum toxin type A | Q84518244 | ||
| Self-maintenance of neurogenic inflammation contributes to a vicious cycle in skin | Q85604678 | ||
| Words of wisdom. Re: Intrathecal administration of botulinum toxin type a improves urinary bladder function and reduces pain in rats with cystitis | Q86914779 | ||
| Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome | Q87155523 | ||
| GAG replenishment therapy for bladder pain syndrome/interstitial cystitis | Q90790254 | ||
| The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin | Q90946609 | ||
| Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues | Q91125877 | ||
| Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis | Q93078697 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | anti-inflammatory agent | Q581996 |
| neuromuscular agents | Q50430099 | ||
| P577 | publication date | 2020-02-03 | |
| P1433 | published in | Toxins | Q15724569 |
| P1476 | title | Effect of Botulinum Toxin A on Bladder Pain-Molecular Evidence and Animal Studies | |
| P478 | volume | 12 |
Search more.